Carlos Maria Ferrario

Prof. Dr. Carlos Maria Ferrario

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Pharmacological Research
Verified
Journal Article
Closed access
CFCarlos Maria Ferrario
Carlos Maria Ferrario
AMAdam E. Mullick
Adam E. Mullick

2 January 2015 in Circulation Research
Verified
Journal Article
Closed access
PDF file
CFCarlos Maria Ferrario
Carlos Maria Ferrario
ESErnesto L. Schiffrin
Ernesto L. Schiffrin
Aldosterone exerts its best known sodium homeostasis actions by controlling sodium excretion at the level of the distal tubules via activation of the apical epithelial sodium channel and the basolateral Na+/K+ATPase pump. Recently, this mineralocorticoid hormone has been demonstrated to act on the heart and blood vessels. Excess release of aldosterone in relation to the salt status induces both genomic and nongenomic effects that by promoting endothelial dysfunction, and vascular and cardiorenal adverse remodeling, contribute to the target organ damage found in hypertension, heart failure, myocardial infarction, and chronic renal failure. Mineralocorticoid receptor blockers have been shown to be highly effective in resistant hypertension and to slow down heart failure progression, and in experimental animals, the development of atherosclerosis. Blockade of the action of aldosterone and potentially other mineralocorticoid steroids has been increasingly demonstrated to be an extremely beneficial therapy in different forms of cardiovascular disease. This review provides a summary of the knowledge that exists on aldosterone actions in the cardiovascular system and, in providing the translational impact of this knowledge to the clinical arena, illustrates how much more needs to be achieved in exploring the use of mineralocorticoid receptor blockers in less advanced stages of heart, renal, and vascular disease.

6 December 2013 in Clinical Science
Verified
Journal Article
Closed access
PDF file
CFCarlos Maria Ferrario
Carlos Maria Ferrario
SASarfaraz Ahmad
Sarfaraz Ahmad
SNSayaka Nagata
Sayaka Nagata
SSStephen W. Simington
Stephen W. Simington
JVJasmina Varagic
Jasmina Varagic
LDLouis Joseph Dell’italia
Louis Joseph Dell’italia
Lessons learned from the characterization of the biological roles of Ang-(1–7) [angiotensin-(1–7)] in opposing the vasoconstrictor, proliferative and prothrombotic actions of AngII (angiotensin II) created an underpinning for a more comprehensive exploration of the multiple pathways by which the RAS (renin–angiotensin system) of blood and tissues regulates homoeostasis and its altered state in disease processes. The present review summarizes the progress that has been made in the novel exploration of intermediate shorter forms of angiotensinogen through the characterization of the expression and functions of the dodecapeptide Ang-(1–12) [angiotensin-(1–12)] in the cardiac production of AngII. The studies reveal significant differences in humans compared with rodents regarding the enzymatic pathway by which Ang-(1–12) undergoes metabolism. Highlights of the research include the demonstration of chymase-directed formation of AngII from Ang-(1–12) in human left atrial myocytes and left ventricular tissue, the presence of robust expression of Ang-(1–12) and chymase in the atrial appendage of subjects with resistant atrial fibrillation, and the preliminary observation of significantly higher Ang-(1–12) expression in human left atrial appendages.

1 May 2024 in Hypertension
Verified
Journal Article
Closed access
MBMichael Bader
Michael Bader
USUlrike Muscha Steckelings
Ulrike Muscha Steckelings
NANatalia Alenina
Natalia Alenina
Robson SantosRobson Santos
Robson Santos
CFCarlos Maria Ferrario
Carlos Maria Ferrario
The renin-angiotensin system is the most important peptide hormone system in the regulation of cardiovascular homeostasis. Its classical arm consists of the enzymes, renin, and angiotensin-converting enzyme, generating angiotensin II from angiotensinogen, which activates its AT 1 receptor, thereby increasing blood pressure, retaining salt and water, and inducing cardiovascular hypertrophy and fibrosis. However, angiotensin II can also activate a second receptor, the AT 2 receptor. Moreover, the removal of the C-terminal phenylalanine from angiotensin II by ACE2 (angiotensin-converting enzyme 2) yields angiotensin-(1-7), and this peptide interacts with its receptor Mas. When the aminoterminal Asp of angiotensin-(1-7) is decarboxylated, alamandine is generated, which activates the Mas-related G-protein-coupled receptor D, MrgD (Mas-related G-protein-coupled receptor type D). Since Mas, MrgD, and the AT 2 receptor have opposing effects to the classical AT 1 receptor, they and the enzymes and peptides activating them are called the alternative or protective arm of the renin-angiotensin system. This review will cover the historical aspects and the current standing of this recent addition to the biology of the renin-angiotensin system.

1 March 2013 in Journal of the American Society of Hypertension
Verified
Journal Article
Closed access
SASarfaraz Ahmad
Sarfaraz Ahmad
CWChih-Chang Wei
Chih-Chang Wei
JTJose Tallaj
Jose Tallaj
LDLouis J. Dell’italia
Louis J. Dell’italia
NMNorihito Moniwa
Norihito Moniwa
CFCarlos Maria Ferrario
Carlos Maria Ferrario

1 August 2016 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
CFCarlos Maria Ferrario
Carlos Maria Ferrario
SASarfaraz Ahmad
Sarfaraz Ahmad
JVJasmina Varagic
Jasmina Varagic
CCChe Ping Cheng
Che Ping Cheng
LGLeanne Groban
Leanne Groban
LDLouis J. Dell′Italia
Louis J. Dell′Italia
Although it is well-known that excess renin angiotensin system (RAS) activity contributes to the pathophysiology of cardiac and vascular disease, tissue-based expression of RAS genes has given rise to the possibility that intracellularly produced angiotensin II (Ang II) may be a critical contributor to disease processes. An extended form of angiotensin I (Ang I), the dodecapeptide angiotensin-(1–12) [Ang-(1–12)], that generates Ang II directly from chymase, particularly in the human heart, reinforces the possibility that an alternative noncanonical renin independent pathway for Ang II formation may be important in explaining the mechanisms by which the hormone contributes to adverse cardiac and vascular remodeling. This review summarizes the work that has been done in evaluating the functional significance of Ang-(1–12) and how this substrate generated from angiotensinogen by a yet to be identified enzyme enhances knowledge about Ang II pathological actions.